DrugPatentWatch Database Preview

Details for Patent: 8,354,409

Which drugs does patent 8,354,409 protect, and when does it expire?

Patent 8,354,409 protects COMBIGAN and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.

Summary for Patent: 8,354,409

Title:	Combination of brimonidine and timolol for topical ophthalmic use
Abstract:	Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/308,507
Patent Claim Types: see list of patent claims	Composition; Use;

Drugs Protected by US Patent 8,354,409

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Allergan	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,354,409

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,474,751	Combination of brimonidine and timolol for topical ophthalmic use	➤ Sign Up
7,323,463	Combination of brimonidine and timolol for topical ophthalmic use	➤ Sign Up
7,642,258	Combination of brimonidine and timolol for topical ophthalmic use	➤ Sign Up
7,030,149	Combination of brimonidine timolol for topical ophthalmic use	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,354,409

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Taiwan	200402296	➤ Sign Up
Taiwan	I351959	➤ Sign Up
Slovenia	1496912	➤ Sign Up
Portugal	1496912	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,354,409

For more information try a trial or see the plans and pricing